CDK9-IN-8

• CAT Number: I019557
• CAS Number: 2105956-51-0
• Molecular Formula: C₃₁H₃₂FN₇O₃
• Molecular Weight: 569.63
• Purity: ≥95%
• IUPAC Name: 1-N-[4-[[7-cyclopentyl-6-(dimethylcarbamoyl)pyrrolo[2,3-d]pyrimidin-2-yl]amino]phenyl]-1-N'-(4-fluorophenyl)cyclopropane-1,1-dicarboxamide
• InChI: InChI=1S/C31H32FN7O3/c1-38(2)27(40)25-17-19-18-33-30(37-26(19)39(25)24-5-3-4-6-24)36-23-13-11-22(12-14-23)35-29(42)31(15-16-31)28(41)34-21-9-7-20(32)8-10-21/h7-14,17-18,24H,3-6,15-16H2,1-2H3,(H,34,41)(H,35,42)(H,33,36,37)
• InChIKey: KXUNYNZTSOIXMY-UHFFFAOYSA-N
• SMILES: CN(C)C(=O)C1=CC2=CN=C(N=C2N1C3CCCC3)NC4=CC=C(C=C4)NC(=O)C5(CC5)C(=O)NC6=CC=C(C=C6)F

CDK9-IN-8 (Cat.No:I019557) is a potent and selective inhibitor of cyclin-dependent kinase 9 (CDK9), an important regulator of transcription elongation. It inhibits CDK9 with an IC50 value of 5.5 nM and exhibits >100-fold selectivity over other CDK family members. CDK9-IN-8 suppresses RNA polymerase II phosphorylation and reduces the expression of key anti-apoptotic proteins, resulting in significant anti-tumor activity in vitro and in vivo. It is being investigated as a potential treatment for various types of cancer.

Reference

[1]. Li Y, et al. Discovery of a highly potent, selective and novel CDK9 inhibitor as an anticancer drug candidate. Bioorg Med Chem Lett. 2017 Aug 1;27(15):3231-3237.